Breakthrough offers fresh hope in fight against Alzheimer’s

Monash University scientists restore memory in promising early study

A promising Australian medical breakthrough is offering fresh hope in the fight against Alzheimer’s disease, after researchers developed a copper-based drug that restored memory and helped clear toxic proteins from the brain in laboratory testing.

Scientists from Monash University say the experimental treatment improved the brain’s natural “waste removal” system, allowing harmful proteins linked to Alzheimer’s to be flushed out more effectively.

The findings, published in Nature Aging, have generated excitement among researchers searching for simpler and more affordable treatments for the devastating condition.

How the treatment works

Alzheimer’s disease is the most common form of dementia, affecting memory, thinking and behaviour. More than 480,000 Australians are currently living with dementia, with numbers expected to rise sharply as the population ages.

The Monash-led team focused on amyloid-beta, a toxic protein that builds up in the brains of people with Alzheimer’s disease.

Rather than targeting the protein directly, researchers worked on improving the brain’s own cleaning system.

Lead researcher Dr Jae Pyun said the brain relies on tiny molecular “pumps” to remove waste products, but these pumps can become damaged over time.

“Think of it like a blocked drain,” Dr Pyun said.

“If the pumps stop working properly, toxic proteins become trapped and start building up in the brain.”

The experimental drug delivers small amounts of copper to help restore the function of those pumps.

Encouraging results

In testing involving mice genetically engineered to develop Alzheimer’s disease, researchers reported a 42 per cent reduction in amyloid-beta build-up.

Memory and learning performance also improved by around 44 per cent compared to untreated mice.

Researchers believe the findings suggest the treatment may help slow, or potentially reverse, some of the damage caused by the disease.

Importantly, the drug compound has already undergone previous safety testing for other medical conditions, which researchers hope could help speed up the pathway towards human clinical trials.

Experts have cautioned the research is still in its early stages and many treatments that work in animals fail during human testing.

Even so, researchers say the study represents an encouraging step forward in the search for new ways to tackle one of the world’s most feared diseases.

Check out Alzheimer’s hope questioned as major review finds limited benefit from anti-amyloid drugs